Fermentation is among the more demanding areas of pharmaceutical manufacturing. Unlike conventional chemical synthesis, commercial success depends on controlling biological processes at scale, optimizing strains and yields, managing complex downstream processing and maintaining batch-to-batch consistency.
These capabilities are built over years rather than acquired simply by installing manufacturing equipment. For Indian biotechnology companies, developing such expertise domestically has also been important in reducing dependence on imported technologies and complex pharmaceutical ingredients.
Concord Biotech Limited has spent more than two decades building its business around precisely this capability. Founded in 2000, the company has evolved from a single-product operation into an integrated biopharmaceutical company with fermentation-based APIs at its core and formulations and CDMO services extending its reach across the value chain. Its expertise today covers complex products across immunosuppressant, antibacterial, antifungal and oncology segments, backed by manufacturing, R&D and regulatory capabilities serving customers across international markets.
Behind this evolution is Sudhir Vaid, Chairman and Managing Director, a microbiologist-turned-entrepreneur with nearly five decades of experience in biotechnology and biopharmaceuticals. His contribution began at a time when fermentation technology remained a relatively specialized field in India. By converting a chemical manufacturing facility at Dholka, Gujarat, into a fermentation and biotechnology hub, Vaid sought to establish something more fundamental than manufacturing capacity: indigenous process knowledge.
His philosophy has remained consistent-India’s advantage in biotechnology cannot be sustained by manufacturing economics alone. Technology, process understanding, scale and global-quality execution have to advance together.
Building Depth in a Difficult-to-Replicate Technology
Concord’s journey has consequently been shaped less by rapid portfolio expansion and more by accumulating expertise in a technically difficult manufacturing discipline. Fermentation requires close control over biological strains, process parameters, productivity, purification and downstream recovery. Small improvements in these areas can materially influence commercial viability, making process knowledge an important competitive asset.
“This accumulated expertise has helped Concord establish a leadership position in immunosuppressant APIs while developing capabilities across other fermentation-based therapeutic categories. Its approach to new products is similarly selective. Rather than adding molecules simply to broaden the portfolio, the company strategically enters products where it believes it can build a meaningful leadership position”, speaks Sudhir Vaid, Chairman and Managing Director.
The period from 2021 to 2026 marked an important progression in this journey. Concord expanded fermentation capacity, strengthened formulations, enhanced its R&D infrastructure and advanced its CDMO capabilities. It also increased penetration into regulated markets. Its public listing during this period further strengthened the company’s corporate profile and provided additional momentum to its growth plans.
The result is a business considerably broader than the fermentation API enterprise from which it originated, without moving away from the scientific specialization that built its position.
Connecting APIs, Formulations and CDMO
The API business remains Concord’s cornerstone and a significant contributor to revenue and profitability. Yet its strategy increasingly revolves around extracting greater value from the scientific and manufacturing infrastructure developed around APIs.
Formulations provide one route. By moving forward in the value chain, Concord can take selected capabilities beyond ingredient manufacturing and participate more deeply in pharmaceutical markets. The segment also creates another avenue for leveraging the company’s knowledge of molecules that it already understands from an API perspective.
"CDMO provides a different extension. Global pharmaceutical innovators increasingly require partners capable of managing technically challenging development and manufacturing assignments without compromising regulatory expectations or commercial scalability. Concord is positioning its fermentation experience, infrastructure and quality systems to address this requirement”, shares Sudhir Vaid.
The significance of this model lies in the overlap among the three businesses. The API operation develops process and manufacturing expertise; formulations enable forward integration; and CDMO allows the same scientific platform to support customer-led development programs.
Concord is now strengthening the CDMO business through additional development capabilities, manufacturing infrastructure and engagement with innovators. Management expects the segment to become a substantially larger contributor as global pharmaceutical companies outsource increasingly complex manufacturing requirements.
Improving the Process, Not Just Expanding Capacity
Concord’s R&D priorities provide a clearer view of how the company intends to protect its fermentation advantage. Its work spans strain development, fermentation optimization, process innovation, yield enhancement, new-product development and complex fermentation-based specialty APIs.
In fermentation manufacturing, these activities have direct commercial consequences. A better-performing strain, improved yield or more efficient downstream process can increase productivity without relying solely on physical capacity additions. R&D therefore functions not merely as a product pipeline engine but also as an operational lever.
“The company is simultaneously expanding fermentation capacities and advanced downstream-processing capabilities. Investments are also being directed towards analytical and quality-control laboratories, formulation manufacturing, automation and digital manufacturing technologies”, adds Sudhir Vaid.
This combination of capacity and process improvement reflects Vaid’s long-standing emphasis on building technology and scale simultaneously. It also creates a stronger base for Concord to handle complicated molecules and customerspecific CDMO programs where reproducibility and scale-up are critical.
Quality remains inseparable from these investments. Concord’s facilities operate according to stringent global standards and undergo inspections by regulatory authorities as well as domestic and international customers. For a company supplying complex products globally, regulatory credibility is not treated as a supporting function but as part of the manufacturing proposition itself.
By moving forward in the value chain, Concord can take selected capabilities beyond ingredient manufacturing and participate more deeply in pharmaceutical markets
Building Customer Proximity Across Global Markets
Concord has developed a diversified international footprint encompassing North America, Europe, Japan, Asia-Pacific, Latin America and other emerging pharmaceutical markets. Importantly, its global strategy is moving beyond supplying these markets from India. The company has established its own marketing presence in the US, Japan and Vietnam, bringing it closer to customers and opportunities in strategically relevant regions.
“This becomes particularly important as pharmaceutical companies reconsider the resilience of global supply chains. Customers seeking additional or alternative sources for complex products require suppliers that already possess the necessary process expertise, quality systems and ability to deliver reliably at commercial scale”, mentions Sudhir Vaid.
Concord sees second-source opportunities and increasing wallet share with existing customers as meaningful growth avenues. Its broad basket of complex fermentation-based APIs provides scope to deepen relationships rather than compete molecule by molecule.
“Trust is earned through consistent performance”, says Sudhir Vaid, Chairman and Managing Director. For Concord, that translates into quality consistency, supply reliability, technical capability and collaborative engagement. Longterm customer relationships have consequently become an important part of the company’s competitive position.
Manufacturing expansion is also being accompanied by greater attention to sustainability. Concord is investing in resource optimization, energy efficiency, water conservation, waste reduction and renewable energy alongside responsible manufacturing and ESG governance.
As international pharmaceutical customers place greater scrutiny on supply-chain sustainability, these capabilities are becoming increasingly connected with global competitiveness.
From Fermentation Manufacturer to Global Biotechnology Partner
Concord’s next phase will be driven by a combination of new products, formulations, CDMO expansion, deeper penetration into regulated markets and continued investment in R&D. The ambition is to develop Concord into a more complete solutions provider in fermentation based biopharmaceuticals - one capable of supporting global pharmaceutical companies through products, development expertise and commercial manufacturing.
For Vaid, this next chapter remains connected to the idea with which Concord began. Indian biotechnology, in his view, has the potential to compete through technology creation rather than technology dependence. Concord’s own evolution - from transforming a chemical facility at Dholka into a fermentation operation to supplying sophisticated products internationally - has been built around that conviction.
Being recognized among the Top Biotechnology Companies therefore carries significance beyond the recognition itself. For Concord, it marks another stage in a journey centered on converting specialized fermentation science into globally competitive pharmaceutical capability.
As the company scales CDMO, complex products and international operations, the same three principles that Vaid associates with its legacy - technology, scale and globalization - continue to define where Concord Biotech intends to go next.
We use cookies to ensure you get the best experience on our website. Read more...
